Larimar Therapeutics Inc (LRMR) - Net Assets
Based on the latest financial reports, Larimar Therapeutics Inc (LRMR) has net assets worth $127.38 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($165.30 Million) and total liabilities ($37.92 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check LRMR PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $127.38 Million |
| % of Total Assets | 77.06% |
| Annual Growth Rate | 19.09% |
| 5-Year Change | 21.23% |
| 10-Year Change | -35.85% |
| Growth Volatility | 118.22 |
Larimar Therapeutics Inc - Net Assets Trend (2012–2025)
This chart illustrates how Larimar Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Larimar Therapeutics Inc market cap and net worth.
Annual Net Assets for Larimar Therapeutics Inc (2012–2025)
The table below shows the annual net assets of Larimar Therapeutics Inc from 2012 to 2025. Also explore Larimar Therapeutics Inc (LRMR) net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $78.08 Million | -54.55% |
| 2024-12-31 | $171.81 Million | +110.24% |
| 2023-12-31 | $81.72 Million | -26.31% |
| 2022-12-31 | $110.90 Million | +72.17% |
| 2021-12-31 | $64.41 Million | -28.18% |
| 2020-12-31 | $89.69 Million | +13023.92% |
| 2019-12-31 | $-694.00K | -100.74% |
| 2018-12-31 | $93.27 Million | +19.25% |
| 2017-12-31 | $78.22 Million | -35.74% |
| 2016-12-31 | $121.73 Million | -28.02% |
| 2015-12-31 | $169.11 Million | +61.92% |
| 2014-12-31 | $104.44 Million | +196.51% |
| 2013-12-31 | $35.22 Million | +337.23% |
| 2012-12-31 | $8.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Larimar Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 37995100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $83.00K | 0.11% |
| Other Comprehensive Income | $54.00K | 0.07% |
| Other Components | $512.78 Million | 656.69% |
| Total Equity | $78.08 Million | 100.00% |
Larimar Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Larimar Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Citra Putra Realty Tbk PT
JK:CLAY
|
$402.08 Million |
|
Bank7 Corp
NASDAQ:BSVN
|
$402.10 Million |
|
Wuxi Acryl Technology Co Ltd
SHG:603722
|
$402.10 Million |
|
HELLOFRESH UNSP.ADS/025
F:HFG0
|
$402.20 Million |
|
Hoang Huy Investment Financial
VN:TCH
|
$401.99 Million |
|
Belo Sun Mining Corp.
TO:BSX
|
$401.86 Million |
|
HiVi Acoustics Technology Co Ltd
SHE:002888
|
$401.85 Million |
|
Eurocharm Holdings Co Ltd
TW:5288
|
$401.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Larimar Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 171,812,000 to 78,085,000, a change of -93,727,000 (-54.6%).
- Net loss of 165,673,000 reduced equity.
- New share issuances of 65,086,000 increased equity.
- Other comprehensive income decreased equity by 94,000.
- Other factors increased equity by 6,954,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-165.67 Million | -212.17% |
| Share Issuances | $65.09 Million | +83.35% |
| Other Comprehensive Income | $-94.00K | -0.12% |
| Other Changes | $6.95 Million | +8.91% |
| Total Change | $- | -54.55% |
Book Value vs Market Value Analysis
This analysis compares Larimar Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.65x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.06x to 3.65x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $3.70 | $3.91 | x |
| 2013-12-31 | $16.17 | $3.91 | x |
| 2014-12-31 | $43.23 | $3.91 | x |
| 2015-12-31 | $75.85 | $3.91 | x |
| 2016-12-31 | $53.51 | $3.91 | x |
| 2017-12-31 | $34.21 | $3.91 | x |
| 2018-12-31 | $34.73 | $3.91 | x |
| 2019-12-31 | $-0.22 | $3.91 | x |
| 2020-12-31 | $7.55 | $3.91 | x |
| 2021-12-31 | $3.75 | $3.91 | x |
| 2022-12-31 | $4.31 | $3.91 | x |
| 2023-12-31 | $1.86 | $3.91 | x |
| 2024-12-31 | $2.80 | $3.91 | x |
| 2025-12-31 | $1.07 | $3.91 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Larimar Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -212.17%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.87x
- Recent ROE (-212.17%) is below the historical average (-66.52%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -172.29% | 0.00% | 0.00x | 1.36x | $-14.69 Million |
| 2013 | -39.82% | 0.00% | 0.00x | 1.08x | $-17.55 Million |
| 2014 | -35.01% | 0.00% | 0.00x | 1.13x | $-47.01 Million |
| 2015 | -43.93% | 0.00% | 0.00x | 1.12x | $-91.20 Million |
| 2016 | -47.55% | 0.00% | 0.00x | 1.08x | $-70.05 Million |
| 2017 | -66.52% | 0.00% | 0.00x | 1.35x | $-59.85 Million |
| 2018 | -65.80% | 0.00% | 0.00x | 1.31x | $-70.70 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-23.06 Million |
| 2020 | -47.19% | 0.00% | 0.00x | 1.17x | $-51.30 Million |
| 2021 | -78.11% | 0.00% | 0.00x | 1.22x | $-56.75 Million |
| 2022 | -30.82% | 0.00% | 0.00x | 1.14x | $-45.27 Million |
| 2023 | -45.21% | 0.00% | 0.00x | 1.17x | $-45.12 Million |
| 2024 | -46.91% | 0.00% | 0.00x | 1.17x | $-97.79 Million |
| 2025 | -212.17% | 0.00% | 0.00x | 1.87x | $-173.48 Million |
Industry Comparison
This section compares Larimar Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,895,707
- Average return on equity (ROE) among peers: -42.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Larimar Therapeutics Inc (LRMR) | $127.38 Million | -172.29% | 0.30x | $402.03 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $109.30 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $170.10 Million | -16.06% | 0.05x | $310.51 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.35 Billion |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.31 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $199.76 Million | -82.32% | 0.11x | $4.61 Billion |
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.